Welch & Forbes’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41.8M Sell
83,322
-5,612
-6% -$2.69M 0.51% 51
2026
Q1
$43.7M Sell
88,934
-150
-0.2% -$81.4K 0.57% 53
2025
Q4
$51.6M Sell
89,084
-642
-0.7% -$363K 0.63% 46
2025
Q3
$43.5M Sell
89,726
-1,388
-2% -$646K 0.52% 54
2025
Q2
$36.9M Sell
91,114
-655
-0.7% -$274K 0.46% 60
2025
Q1
$45.7M Buy
91,769
+738
+0.8% +$400K 0.6% 47
2024
Q4
$47.4M Sell
91,031
-3,246
-3% -$1.78M 0.61% 44
2024
Q3
$58.3M Buy
94,277
+384
+0.4% +$227K 0.74% 43
2024
Q2
$50.7M Buy
93,893
+25
+0% +$14.3K 0.68% 43
2024
Q1
$54.6M Buy
93,868
+6,231
+7% +$3.5M 0.75% 41
2023
Q4
$46.5M Buy
87,637
+66
+0.1% +$31.9K 0.7% 43
2023
Q3
$44.3M Buy
87,571
+3,586
+4% +$1.91M 0.73% 43
2023
Q2
$43.8M Buy
83,985
+1,642
+2% +$886K 0.69% 45
2023
Q1
$47.5M Buy
82,343
+1,274
+2% +$718K 0.8% 38
2022
Q4
$44.6M Sell
81,069
-307
-0.4% -$163K 0.8% 38
2022
Q3
$41.3M Buy
81,376
+758
+0.9% +$424K 0.81% 39
2022
Q2
$43.8M Buy
80,618
+2,099
+3% +$1.16M 0.8% 40
2022
Q1
$46.4M Buy
78,519
+2,392
+3% +$1.37M 0.73% 41
2021
Q4
$50.8M Buy
76,127
+302
+0.4% +$189K 0.76% 39
2021
Q3
$43.3M Buy
75,825
+2,684
+4% +$1.47M 0.72% 40
2021
Q2
$36.9M Buy
73,141
+3,210
+5% +$1.51M 0.62% 47
2021
Q1
$31.9M Buy
69,931
+2,008
+3% +$958K 0.59% 50
2020
Q4
$31.6M Buy
67,923
+482
+0.7% +$226K 0.62% 46
2020
Q3
$29.8M Buy
67,441
+1,347
+2% +$557K 0.64% 46
2020
Q2
$23.9M Buy
66,094
+3,294
+5% +$1.1M 0.56% 52
2020
Q1
$17.8M Buy
62,800
+2,676
+4% +$844K 0.5% 61
2019
Q4
$19.5M Buy
60,124
+725
+1% +$220K 0.43% 68
2019
Q3
$17.3M Buy
59,399
+1,755
+3% +$503K 0.41% 70
2019
Q2
$16.9M Buy
57,644
+2,371
+4% +$653K 0.41% 68
2019
Q1
$15.1M Buy
55,273
+1,990
+4% +$495K 0.38% 76
2018
Q4
$11.9M Buy
53,283
+1,855
+4% +$435K 0.34% 80
2018
Q3
$12.6M Buy
51,428
+3,473
+7% +$799K 0.3% 91
2018
Q2
$9.93M Buy
47,955
+35,913
+298% +$7.62M 0.26% 95
2018
Q1
$2.49M Sell
12,042
-11
-0.1% -$2.31K 0.06% 163
2017
Q4
$2.29M Sell
12,053
-95
-0.8% -$18.2K 0.06% 159
2017
Q3
$2.3M Hold
12,148
0.06% 162
2017
Q2
$2.12M Buy
12,148
+34
+0.3% +$5.71K 0.06% 163
2017
Q1
$1.86M Sell
12,114
-334
-3% -$51K 0.05% 168
2016
Q4
$1.76M Buy
12,448
+1,310
+12% +$193K 0.05% 170
2016
Q3
$1.77M Sell
11,138
-265
-2% -$40.8K 0.06% 147
2016
Q2
$1.69M Sell
11,403
-200
-2% -$29.5K 0.05% 169
2016
Q1
$1.64M Buy
11,603
+262
+2% +$35.1K 0.05% 170
2015
Q4
$1.61M Sell
11,341
-1,221
-10% -$163K 0.05% 169
2015
Q3
$1.54M Sell
12,562
-423
-3% -$55.1K 0.05% 177
2015
Q2
$1.69M Buy
12,985
+3,350
+35% +$437K 0.05% 173
2015
Q1
$1.29M Sell
9,635
-202
-2% -$26K 0.04% 195
2014
Q4
$1.23M Sell
9,837
-229
-2% -$27.8K 0.04% 201
2014
Q3
$1.23M Sell
10,066
-1,440
-13% -$175K 0.04% 204
2014
Q2
$1.36M Buy
11,506
+840
+8% +$98.9K 0.04% 182
2014
Q1
$1.28M Buy
10,666
+1,950
+22% +$232K 0.04% 193
2013
Q4
$970K Buy
8,716
+150
+2% +$14.9K 0.03% 201
2013
Q3
$790K Buy
8,566
+1,176
+16% +$106K 0.03% 216
2013
Q2
$625K Buy
+7,390
New +$615K 0.02% 215

Other funds holding TMO

Welch & Forbes's TMO Position: Q2 2026 in Review

Welch & Forbes reduced its Thermo Fisher Scientific (TMO) stake by 6.3% in Q2 2026, selling an estimated $2.69M and leaving 83,322 shares worth $41.8M. The position accounts for 0.51% of the portfolio, ranked #51.

Welch & Forbes first reported a position in TMO in Q2 2013 and has held it in 53 quarters since. The position peaked at $58.3M in Q3 2024. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Welch & Forbes held 83,322 shares of Thermo Fisher Scientific worth $41.8M as of Q2 2026.
  • Welch & Forbes sold 5,612 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.69M.
  • Thermo Fisher Scientific made up 0.51% of Welch & Forbes's portfolio in Q2 2026, its #51 holding.
  • Welch & Forbes first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 53 quarters since.
  • Welch & Forbes's Thermo Fisher Scientific position peaked at $58.3M in Q3 2024.
  • 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Welch & Forbes's 13F filing for Q2 2026, filed 30 Jul 2026.